Journal of Chemotherapy最新文献_第4页

Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges. 单侧面神经麻痹后延长每周紫杉醇治疗：一个罕见的病例颅神经毒性与诊断挑战。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-07-28 DOI: 10.1080/1120009X.2025.2538945

Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan

{"title":"Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges.","authors":"Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan","doi":"10.1080/1120009X.2025.2538945","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2538945","url":null,"abstract":"Background: Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer. While peripheral neuropathy is a well-recognized dose-limiting toxicity of paclitaxel, cranial nerve involvement remains exceptionally rare. We report a case of unilateral facial nerve palsy in a breast cancer patient receiving standard-dose paclitaxel therapy, highlighting the diagnostic challenges in distinguishing drug-induced neurotoxicity from other aetiologies.Case report: A 43-year-old woman with metastatic breast cancer developed left facial nerve paralysis after 12 months of weekly paclitaxel treatment (80 mg/m2). Contrast-enhanced cranial Magnetic Resonance Imaging (MRI) demonstrated bilateral cranial nerve VII enhancement, creating diagnostic uncertainty between leptomeningeal metastasis, paclitaxel-induced neuritis, and idiopathic Bell's palsy. Paclitaxel was discontinued, and corticosteroid therapy was initiated. Clinical and radiological improvement at follow-up strongly supported a drug-related aetiology.Conclusion: This case illustrates the diagnostic complexity of facial nerve palsy in cancer patients receiving neurotoxic chemotherapy. The overlapping clinical and radiological features between drug-induced cranial neurotoxicity, leptomeningeal disease, and idiopathic causes present significant diagnostic challenges. Clinicians should maintain a high degree of suspicion for rare chemotherapy-related cranial neuropathies while pursuing comprehensive differential diagnosis, including infectious aetiologies and metastatic disease.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis. 卡莫来珠单抗联合经动脉化疗栓塞介入治疗肝癌合并肝硬化的临床评价

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-25 DOI: 10.1080/1120009X.2025.2535821

Jian Chen, Mengshan Huang

{"title":"Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis.","authors":"Jian Chen, Mengshan Huang","doi":"10.1080/1120009X.2025.2535821","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2535821","url":null,"abstract":"This retrospective study evaluated the clinical efficacy of camrelizumab combined with transarterial chemoembolization (TACE) in 120 hepatocellular carcinoma (HCC) patients with liver cirrhosis. Based on the intervention received, patients were categorized into an observation group (OG) (n = 60, underwent camrelizumab combined with TACE interventional therapy) and a control group (CG) (n = 60, underwent camrelizumab monotherapy). The OG showed significantly higher objective response (66.67% vs. 46.67%) and disease control rates (91.67% vs. 80.00%), improved immune function (elevated CD3+, CD4+, CD4+/CD8+), better liver function (reduced TB and ALT), and reduced tumor markers (AFP, CEA) compared to the CG. One-year follow-up revealed prolonged overall survival rate and progression-free survival, along with better quality-of-life scores in the OG. These findings suggest that camrelizumab combined with TACE demonstrates definitive short-term efficacy, improved immune and liver function, better survival outcomes, and favorable safety in HCC patients with liver cirrhosis, supporting its clinical value.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives. 靶向白血病干细胞：通过tivantinib （ARQ197）和asciminib （ABL001）增强根除与分子对接引导的治疗衍生物筛选

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-25 DOI: 10.1080/1120009X.2025.2532948

İlknur Karatekin Arik, Nurcan Gümüş, İlayda Alcitepe, Cumhur Gündüz, Belgin Sever, Halil İbrahim Ciftci, Güray Saydam, Burçin Tezcanli Kaymaz

{"title":"Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives.","authors":"İlknur Karatekin Arik, Nurcan Gümüş, İlayda Alcitepe, Cumhur Gündüz, Belgin Sever, Halil İbrahim Ciftci, Güray Saydam, Burçin Tezcanli Kaymaz","doi":"10.1080/1120009X.2025.2532948","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2532948","url":null,"abstract":"This study is the first to investigate the therapeutic potential of a mono/combination treatment with the selective phase III BCR::ABL1 tyrosine kinase inhibitor (TKI) asciminib (ABL001) and the c-MET inhibitor tivantinib (ARQ197) in hematopoietic stem cells (HSCs) and leukaemia stem cells (LSCs) in terms of cytotoxicity, apoptosis, target gene expression profiles, and bioinformatics in vitro. In silico studies were also performed for various tivantinib and asciminib derivatives. Asciminib and tivantinib exhibited significant antileukaemic effects, with tivantinib showing the strongest apoptotic impact in LSCs and asciminib in HSCs. Although their combination exhibited an additive effect on LSCs, enabling dose reduction and potentially minimizing side effects; the treatment succeeded in promoting apoptosis as effectively as tivatinib monotherapy. Gene expression analysis showed increased pro-apoptotic and tumour suppressor markers, whereas decreased oncogenes' expressions following mono/combined treatment in LSCs. Molecular docking showed that a new analogue of tivantinib (compound-1) and CHEMBL5274046 are promising c-MET and ABL1 inhibitors, respectively. The findings highlight the antileukaemic potential of initially tivantinib and asciminib in LSCs. Despite an additive effect, combination therapy allowed dose reduction, giving rise to a potential decrease in side effects. Targeting c-MET, alone or in combination with BCR::ABL1 inhibition, presents a compelling strategy for eradicating LSCs, which underpin resistance and relapse in CML therapy - thus marking a crucial advancement in the pursuit of more effective treatment paradigms. In silico studies indicated that various tivantinib and asciminib analogues could also have potential therapeutic effects as c-MET and ABL1 inhibitors for future anti-leukaemia research.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-20"},"PeriodicalIF":1.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a retrospective study. 氟喹替尼单药与氟喹替尼联合免疫检查点抑制剂治疗晚期结直肠癌的疗效比较：一项回顾性研究

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-16 DOI: 10.1080/1120009X.2025.2532912

Li Huang, Hui Rao, Chunmei Wu, Xiaohui Liu, Yipeng Song, Gangfeng Zhu, Miao He

{"title":"Comparison of the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a retrospective study.","authors":"Li Huang, Hui Rao, Chunmei Wu, Xiaohui Liu, Yipeng Song, Gangfeng Zhu, Miao He","doi":"10.1080/1120009X.2025.2532912","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2532912","url":null,"abstract":"This study explored the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced proficient mismatch repair/microsatellite stable-type colorectal cancer. We retrospectively collected data from patients (n=75) diagnosed with advanced colorectal cancer at our hospital from January 2020 to December 2022 who chose to receive fruquintinib monotherapy or combine it with immune checkpoint inhibitors for treatment. The primary endpoint was progression-free survival (PFS) and overall survival (OS). As of July 1, 2023, the median PFS for the fruquintinib monotherapy group and combination therapy was 3.9 months and 7.9 months , respectively (P = 0.142). The median OS in the monotherapy group and combination therapy was 10.3 months and 10.0 months, respectively (P = 0.942). However, as compared with the monotherapy group, the combination therapy group showed a trend for a prolonged duration of PFS, and it may have good application potential.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia. 确定与生存相关的遗传生物标志物，以发现急性髓性白血病的新治疗靶点。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-05 DOI: 10.1080/1120009X.2025.2527464

Cansu Ergun, Yağmur Kiraz, Gizem Ayna Duran

{"title":"Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia.","authors":"Cansu Ergun, Yağmur Kiraz, Gizem Ayna Duran","doi":"10.1080/1120009X.2025.2527464","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2527464","url":null,"abstract":"Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-17"},"PeriodicalIF":1.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated CK from immune checkpoint inhibitor- related hypophysitis: a case report. 与免疫检查点抑制剂相关的肾上腺皮质功能减退引起的肌酸激酶升高：病例报告。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-01 Epub Date: 2024-05-31 DOI: 10.1080/1120009X.2024.2359838

Jasmine Gill, John Walker, Carrie Ye

引用次数: 0

Real-world outcomes of metastatic clear cell sarcoma sequential chemotherapy. 转移性透明细胞肉瘤序贯化疗的实际效果。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-01 Epub Date: 2024-07-08 DOI: 10.1080/1120009X.2024.2372524

Anna M Czarnecka, Paulina Chmiel, Piotr J Błoński, Tomasz Świtaj, Paweł Rogala, Sławomir Falkowski, Hanna Koseła-Paterczyk, Paweł Teterycz, Tadeusz Morysiński, Mateusz Spałek, Michał Wągrodzki, Piotr Rutkowski

{"title":"Real-world outcomes of metastatic clear cell sarcoma sequential chemotherapy.","authors":"Anna M Czarnecka, Paulina Chmiel, Piotr J Błoński, Tomasz Świtaj, Paweł Rogala, Sławomir Falkowski, Hanna Koseła-Paterczyk, Paweł Teterycz, Tadeusz Morysiński, Mateusz Spałek, Michał Wągrodzki, Piotr Rutkowski","doi":"10.1080/1120009X.2024.2372524","DOIUrl":"10.1080/1120009X.2024.2372524","url":null,"abstract":"Clear cell sarcoma is an ultra-rare chemoresistant subtype of soft tissue sarcoma. This retrospective analysis aimed to clarify the efficacy of palliative chemotherapy in CCS by assessing response rates, progression-free survival (PFS), and overall survival (OS) at a referral center. A retrospective analysis of palliative treatment was conducted on patients with CCS treated at the sarcoma unit from 1997 to 2023. Treatment responses were assessed using RECIST criteria, and the Kaplan-Meier method was used to calculate PFS and OS. The analysis covered 23 CCS chemotherapy-treated patients with 11 (47.8%) men. The median age at the palliative treatment start was 32 years (range 18-59). The median follow-up was 8.2 months. Four patients were referred to our centre for M1 disease, and 6 received perioperative chemotherapy and progressed during follow-up. In the first line, 14 patients received anthracycline-based chemotherapy (60.9%), five were treated with ifosfamide (HD-IFO), and four received other regimens. One patient (4.3%) achieved partial response (PR), and 12 patients (52.2%) achieved stable disease (SD) as the best response. Median PFS in 1 line was 2.79 months (95% CI: 2.04-8.38), and 1.76 months (95% CI: 0.72-6.97) in the second line. The median OS from first-line palliative chemotherapy was 8.2 months (95% CI: 6.2-14), and the second-line palliative chemotherapy mOS was 4.6 months (95% CI: 3.9-NA). Perioperatively anthracycline-pretreated worsened patients' median PFS in the M1 setting. Poor responses to conventional chemotherapy were observed in CCS, indicating a need for further clinical trials in this indication.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"341-352"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of hereditary hemorrhagic telangiectasia-like symptoms induced by trastuzumab emtansine in a breast cancer patient: case report. 一名乳腺癌患者因曲妥珠单抗诱发遗传性出血性毛细血管扩张症样症状的处理：病例报告。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-01 Epub Date: 2024-07-19 DOI: 10.1080/1120009X.2024.2379169

Micaela Tyburec, Ana Braslavsky, Candelaria Serrano, Carolina Vázquez, Marcelo Serra

{"title":"Management of hereditary hemorrhagic telangiectasia-like symptoms induced by trastuzumab emtansine in a breast cancer patient: case report.","authors":"Micaela Tyburec, Ana Braslavsky, Candelaria Serrano, Carolina Vázquez, Marcelo Serra","doi":"10.1080/1120009X.2024.2379169","DOIUrl":"10.1080/1120009X.2024.2379169","url":null,"abstract":"Trastuzumab emtansine (T-DM1) is a targeted therapy combining trastuzumab and emtansine for human epidermal growth factor receptor 2(HER2)-positive breast cancer, with common side effects including fatigue, nausea, pain, headache, low platelet count, and elevated liver enzymes. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular dysplasia characterized by vascular malformations and telangiectasias in various organs. We present a case of a female patient with advanced breast cancer who developed HHT-like symptoms while on T-DM1 treatment. A 59-year-old woman treated with radiotherapy and T-DM1 every 21 days developed recurring nosebleeds and mucocutaneous and liver telangiectasias indistinguishable from HHT three months after receiving the first dose of T-DM1. Other organ vascular malformations were ruled out through screening protocols. The patient had no previous HHT symptoms or family history. Nasal care measures like lubrication and antifibrinolytics (tranexamic acid) were provided. In addition, propranolol was also prescribed due to its antiangiogenic and antitumoral properties, leading to significantly decreased epistaxis and telangiectasias. Microtubule disruptions caused by T-DM1, along with other angiogenic mechanisms may contribute to the development of telangiectasias resembling HHT. The use of propranolol, an initial approach for HHT, proved to be effective in this case. It is crucial for oncologists and HHT specialists to be aware of this rare adverse event associated with T-DM1 and to implement appropriate management strategies.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"383-387"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Camrelizumab-induced anaphylactic reaction: a case report and literature review. Camrelizumab 引起的过敏反应：病例报告和文献综述。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-01 Epub Date: 2024-06-27 DOI: 10.1080/1120009X.2024.2372525

Jiarui Hu, Jieting Fan, Shaobo Qu, Xiaohua He, Daiwei Liu, Yongxia Wang, Xiaoyuan Wu, Zhanlin Li

{"title":"Camrelizumab-induced anaphylactic reaction: a case report and literature review.","authors":"Jiarui Hu, Jieting Fan, Shaobo Qu, Xiaohua He, Daiwei Liu, Yongxia Wang, Xiaoyuan Wu, Zhanlin Li","doi":"10.1080/1120009X.2024.2372525","DOIUrl":"10.1080/1120009X.2024.2372525","url":null,"abstract":"Camrelizumab is an immune checkpoint inhibitor clinically used to treat various types of tumours. In this study, the authors provided the first report of a case of an anaphylactic reaction induced by camrelizumab in the treatment of a patient with squamous cell carcinoma of the floor of the mouth. The patient, a 58-year-old man, was diagnosed with advanced squamous cell carcinoma of the floor of the mouth, with cancer infiltration and multiple metastases. He underwent treatment for nine cycles, in which cycles 1-5 he received camrelizumab, albumin-bound paclitaxel, and cisplatin (200 mg of camrelizumab each time, every 3 weeks), with no adverse reactions; in cycle 6, he received albumin-bound paclitaxel and cisplatin, with no adverse reactions; and in cycles 7-9, he received camrelizumab and albumin-bound paclitaxel. However, 30 min after 8th administration of camrelizumab (cycle 9), he suddenly developed sweating, a pale complexion, clamminess and cyanosis of the limbs (percutaneous arterial oxygen saturation [SpO2] = 82%, blood pressure [BP] = 79/49 mmHg, heart rate [HR] = 83 beats/min [bpm] and respiratory rate [RR) = 12 bpm). The patient underwent intravenous infusion of methylprednisolone (80 mg) combined with dopamine to boost the BP; he regained consciousness 20 min later, and many parts of his skin appeared smooth, with no desquamation and accompanied by itching erythema, especially on the upper limbs. Approximately 2 h after treatment, the patient's skin erythema subsided (vital sign monitoring results: SpO2 = 100%, BP = 122/84 mmHg, HR = 91 bpm and RR = 17 bpm); the patient did not complain about his obvious discomfort. Despite the rarity of acute anaphylactic reactions among immune-related adverse reactions, great importance should be given to anaphylactic reactions of camrelizumab due to its extensive clinical application.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"376-382"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141468356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma. 利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松龙（R-CHOP）疗法会降低 B 细胞非霍奇金淋巴瘤患者的瘦体重和骨骼肌质量指数，即使在最终治疗一年后也是如此。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-01 Epub Date: 2024-07-11 DOI: 10.1080/1120009X.2024.2376454

Sanshiro Nakao, Daiji Ngayama, Chiaki Nakaseko, Naomi Shimizu

{"title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma.","authors":"Sanshiro Nakao, Daiji Ngayama, Chiaki Nakaseko, Naomi Shimizu","doi":"10.1080/1120009X.2024.2376454","DOIUrl":"10.1080/1120009X.2024.2376454","url":null,"abstract":"Sarcopenia is an independent prognostic factor for several solid cancers, including B-cell non-Hodgkin lymphoma (B-NHL). However, previous reports have measured the parameters of loss of skeletal muscle as sarcopenia only once before chemotherapy and have predicted poor outcomes. In this study, changes in body composition were measured in patients who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy for B-NHL using the InBody 720 analyzer throughout the therapy. Twenty-seven patients who achieved complete remission and survived for one year after the last cycle were included in the study. Body composition was evaluated immediately before initiation and fourth cycle, and one month and one year after the last cycle. Throughout the follow-up period, the lean body mass index (LBMI) and appendicular skeletal muscle mass index (ASMI) showed significant transient decreases even one year following the last cycle (p < 0.001, p = 0.002, respectively). Body fat index (BFI) and body fat percentage (BF%) decreased until one month after the last cycle; however, they reached levels higher than the baseline levels, +22.1% and +15.9%, respectively, at 1 year from the last cycle. The loss of skeletal muscle mass did not recover even one year after the last cycle. Interventions in nutritional management are needed to prevent sarcopenia in patients treated with R-CHOP therapy.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"365-371"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0